HCPCS Level II code Q9983 denotes florbetaben F18, billed per study dose (up to 8.1 millicuries), for diagnostic PET imaging typically used in visualization of cerebral amyloid. This radiopharmaceutical code matters nationally because PET amyloid imaging has implications for diagnostic pathways in cognitive disorders and for payer coverage determinations that affect access to advanced neuroimaging.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and reimbursement context across major national payers, benchmark metrics where available, and the relevant clinical context for use of florbetaben F18 in PET studies.

The publication outlines the clinical indication and service setting for the code, typical billing considerations, and comparisons of payer approaches to covering amyloid PET agents. It also summarizes policy and coding factors that affect utilization and claims processing for radiopharmaceutical diagnostic doses. Data not available in the input is clearly noted where applicable.